The impact of cohort substance use upon likelihood of transitioning through stages of alcohol and cannabis use and use disorder: Findings from the Australian National Survey on Mental Health and Wellbeing
Year: 2018
Type: article
Abstract: INTRODUCTION AND AIMS: We used population-level Australian data to estimate prevalence, age of onset and speed of transitions across stages of alcohol and cannabis use, abuse and dependence, and remission from disorder, and consider the potential impacts that an individual's age cohort's level of substance use predicted transitions into and out of substance use. DESIGN AND METHODS: Data on use, DSM-IV use disorders, and remission from these disorders were collected from participants (n = 8463) in the 2007 Australian National Survey of Mental Health and Wellbeing using the Composite International Diagnostic Interview. RESULTS: Lifetime prevalence (95% confidence interval) of alcohol use, regular use, abuse and dependence were 94.1% (93.3-94.8%), 64.5% (62.9-66.2%), 18.7% (17.4-19.9%) and 4.0% (3.4-4.6%). Lifetime prevalence of cannabis use, abuse and dependence were 19.8% (18.6-20.9%), 4.4% (3.8-5.0%) and 1.9% (1.5-2.4%). Among those with the disorder, rates of remission from cannabis abuse, alcohol abuse, cannabis dependence and alcohol dependence were 90.5% (87.4-93.6%), 86.2% (83.8-88.7%), 79.6% (71.1-88.1%) and 53.8% (46.6-61.0%). Increases in the estimated proportion of people in the respondent's age cohort who used alcohol/cannabis as of a given age were significantly associated with most transitions from use through to remission beginning at the same age. DISCUSSION AND CONCLUSIONS: Clear associations were documented between cohort-level prevalence of substance use and personal risk of subsequent transitions of individuals in the cohort from use to greater substance involvement. This relationship remained significant over and above associations involving the individual's age of initiation. These findings have important implications for our understanding of the causal pathways into and out of problematic substance use.
Source: Drug and Alcohol Review
DOI: 10.1111/dar.12679
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: U.S. Department of Health and Human Services, John D. and Catherine T. MacArthur Foundation, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, GlaxoSmithKline, Sanofi, World Health Organization, Shire, Indivior, Seqirus, Pfizer Foundation, Pan American Health Organization, Medical Research Council, National Health and Medical Research Council, National Institute of Mental Health, National Institute on Drug Abuse, Fogarty International Center
Awards: World Mental Health Consortium Annual Meeting 2003-07, Social Role Disability and Mental-Physical Co-Morbidity, Toward a comprehensive picture of the epidemiology of alcohol and illicit drug use disorders: Novel analyses of the World Health Organization's World Mental Health Surveys, CROSS-NATIONAL STUDIES OF DRUG INVOLVEMENT: WMH2000, G3658001182, G4504230253, Risk Factors for Psychopathology in the WHO WMH Surveys, Epidemiology - National Comorbidity Survey Replication, Using existing data to understand and ameliorate risk in opioid agonist therapy, Lebanon-Epidemiology: The NCS Replication Study
OpenAlex ID: W2794263390
